A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
Study sponsor: Ultragenyx Pharmaceutical Inc · RARE
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-03Estimated
Enrollment · participants82Estimated
Source updated2026-09-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.